1. REVIVED-BCIS2: Stable CAD Is Very Stable
At our hospital and probably yours too, patients with an undiagnosed cardiomyopathy are sent for coronary angiography. The purpose is to diagnose coronary artery disease (CAD), presumably because revascularizing it would improve ventricular function and outcomes.
The results of the REVIVED-BCIS2 trial upends the logic of this common practice. British investigators gave percutaneous coronary intervention (PCI) a near-perfect opportunity to shine. They randomly assigned 700 patients with ischemic cardiomyopathy (left ventricular ejection fraction [LVEF] ≤ 35%) and anatomy amenable to PCI and substantial myocardial viability to either PCI or optimal medical therapy.
During 3.5 years, there was no difference in the primary outcome of death or hospitalization for heart failure (37.2% vs 38.0%). There were also no significant differences in LVEF or quality-of-life score. Pause here and imagine an angiogram with multivessel severe CAD and amenable lesions—and a cardiologist choosing medicines over stents.
Cardiac surgeons might argue that surgery would have fared better. In 5-year follow-up of STICH, a relatively similar group of patients sustained a near-significant 14% lower rate of death or hospitalization for cardiac causes with surgery vs medical therapy. And at 10-year follow-up, the 16% reduction in the primary endpoint with surgery did meet the threshold for significance. The rebuttal, however, is that medical therapy has improved greatly over the past decade, and surgery carries significant upfront risk.
This trial is not only a practice changer; it’s a thinking changer: stable CAD is very stable and medical therapy is darn good. No trial shows this more strongly than REVIVED-BCIS2.
2. Patient Selection for Percutaneous Left Atrial Appendage Occlusion
In 2022, doctors increasingly embraced percutaneous left atrial appendage occlusion or closure (LAAO). Regular readers know my skepticism of this procedure, which remains unchanged. That is not the story this year.
This year’s story was a series of studies suggesting dubious patient selection. The goal of LAAO is to eliminate the left atrial appendage as a source of cardiac emboli. The benefits should accrue—over time—through reduced stroke and reduced bleeding because anatomic plugging allows for reducing antithrombotic burden.
This requires two key factors: selection of patients with minimal competing causes of stroke and a lifespan long enough for net benefits to accrue. In January, Watchman investigators suggested that net benefit of the device over the Watchman device (Boston Scientific, Marlborough, Massachusetts) began at about 3 years. Series published this year from Spain, Israel, and the United States all found that clinicians are choosing older patients with frailty, significant comorbidities, and limited lifespan. A study comparing patients who received the device in trials vs registries found that mortality rates were more than twofold greater in the real world than in trials.
No matter your view of percutaneous closure, the increasing use of this device in patients least likely to benefit is a worrisome trend.
3. The 2022 Spin Award: GUIDE-HF
A decade before the CardioMEMS HF System (Abbott, Abbott Park, Illinois), the paperclip-sized pulmonary artery (PA) device, was developed, another PA catheter, called the Swan-Ganz catheter, was found to be ineffective in three randomized controlled trials. The wireless CardioMEMS HF System is PA monitoring 2.0 for outpatients.
The device had been U.S. Food and Drug Administration (FDA) approved for a highly selected group of patients with heart failure. The GUIDE-HF trial investigators randomly assigned a broader group of 1000 patients to CardioMEMS-based management vs standard care. The stakes were high: if the $20,000 device passed muster, it stood to be expanded to over a million more patients. You do the math.
The GUIDE-HF investigators reported a nonsignificant 12% reduction in the primary endpoint of death, urgent heart failure visit, or hospitalization for heart failure (HR, 0.88; 95% CI, 0.75 - 1.05; P = .16). Because that is far from our accepted threshold of significance, you would have thought the FDA would have declined labeling for the broader indication.
But that is not what happened. Instead, the authors, in consultation with the FDA, reported a pre-COVID analysis. Slightly more than two thirds of patients in the trial finished their follow-up before the lockdowns. In an analysis of this subgroup, the hazard reduction was now 19% and the P value eked by at .05. Voila, the FDA approved the device on the basis of this analysis.
The problems are many. The most worrisome is that in the 28% of patients followed during the pandemic, the wireless device, which should cut down on in-person visits, underperformed. During this time there were no differences in any component of the endpoints.
I wrote about these issues in March, making the case that underperformance of the device during a time when the pandemic raised the bar for hospitalizations suggests that pre-COVID reductions in heart failure hospitalizations were likely due to performance bias.
As I write this review, CardioMEMS advertisements adorn our breakrooms, interventional cardiologists implant the device, heart failure clinicians embrace the data, and payers pay. Meanwhile, disparities in healthcare outcomes for the under- and uninsured worsen.
4. Exemplary Science
I gave a lecture this year on critical appraisal tips and tricks. The intro slides ask a reader to first consider whether a trial is for science or marketing.
I use the CHAP trial on treating mild hypertension during pregnancy as an example of a trial seeking to answer an important scientific question. Hypertension affects about 2% of all pregnancies; it results in substantial risks to both child and mom. And it disproportionately affects Black women.
Funded by the National Institutes of Health, the CHAP trialists randomly assigned more than 2400 pregnant women with mild chronic hypertension to a medical regimen to reduce their blood pressure to 140/90 mm Hg or less vs a control arm of no medicines unless the blood pressure was 160/90 mm Hg or greater. They found a statistically significant 18% reduction in the primary endpoint of pre-eclampsia with severe features, preterm birth, placental abruption, or fetal or neonatal death. The nearly 5–percentage point absolute risk reduction was also clinically meaningful.
These findings strongly support a strategy of using medications to target a lower blood pressure rather than reserving therapy for higher blood pressures. Before this trial there was uncertainty. CHAP makes the top 10 list because it was an exemplary use of taxpayer resources to answer an important scientific question.
5. Big Electrophysiology Innovations
There were three (potentially) big developments in my field of electrophysiology in 2022.
One is a new way to ablate cardiac myocytes called pulsed field ablation (PFA). PFA uses short electrical pulses to disrupt cell membranes. The novelty is that it is cardioselective and does not affect adjacent structures, such as the phrenic nerve or esophagus. Many European centers have adopted PFA. It may not improve ablation efficacy, but avoiding esophageal injury would be a huge advance.
Patients with severe vasovagal syncope can be difficult to treat. These are often young people, who may face a lifetime with a pacemaker. Cardioneural ablation is a technique in which standard radiofrequency ablation can be used to target ganglionated plexi, which are close to where we ablate during atrial fibrillation ablation. Early reports are promising, but essentially all therapies for vasovagal conditions have failed in sham-controlled studies.
Pacing-induced cardiomyopathy used to be the price for implanting pacemakers for bradycardia. His-bundle pacing showed us that we could pace the heart without creating dyssynchrony, but it had downsides. In 2022, electrophysiologists increasingly adopted left bundle-branch area pacing, which is much easier to do and is associated with better pacing parameters. A small randomized trial showed early evidence that it may be as good as or better than standard biventricular pacing. This year we learned that the U.S. government will fund a large trial comparing left bundle-branch pacing to standard cardiac resynchronization therapy.
6. Screening for Disease
It is really hard to show survival benefits from screening for disease. Even if a screening test led to a reduction in death from one disease, there are thousands of competing causes of death.
The DANCAVAS trial showed us that an invitation to a comprehensive but efficient cardiovascular screening program might actually improve survival—if you are able to suspend binary thinking about P value thresholds.
- 3
© 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: John M. Mandrola. Mandrola’s Top 10 Cardiology Stories of 2022 - Medscape - Dec 15, 2022.